STRAFFORD WEBINAR
APRIL 30, 2024
1:00 PM ET — 2:30 PM ET
Despite not using march-in rights over the past 40 years to limit drug pricing, the Biden administration and governmental agencies are now turning to march-in as a potential means to lower drug pricing. Under the Bayh-Dole Act, the federal government has the right to “march in” on patented inventions created using federal funds to require the patent holder to license the patent to other applicants.
Foley Hoag partner Donald Ware will join this Strafford panel to review the history of the Bayh-Dole Act, lessons learned from past march-in petitions and the proposed NIST framework. The panel will discuss the implications and concerns for patent rights and innovation in the biopharma space.